The city of Ann Arbor, Michigan, currently has 54 active clinical trials seeking participants for Lymphoma research studies.
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma
Recruiting
Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL). Part 2: Cohort Expansion. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability of KB-0742 in defined participant cohorts.
Gender:
All
Ages:
12 years and above
Trial Updated:
01/31/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Recruiting
This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and eve... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Recruiting
The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Recruiting
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Saint Joseph Mercy Hospital, Ann Arbor, Michigan
Conditions: Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Recruiting
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone m... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/21/2023
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: CD20 Positive, Mantle Cell Lymphoma
A Study Of The Selective PKC-β Inhibitor MS- 553
Recruiting
A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2023
Locations: University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma